- Home
- JAGX vs SCNI Comparison
JAGX vs SCNI Comparison
Compare JAGX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- SCNI
- Stock Information
- Founded
- JAGX 2013
- SCNI 2003
- Country
- JAGX United States
- SCNI Israel
- Employees
- JAGX N/A
- SCNI N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JAGX Health Care
- SCNI Health Care
- Exchange
- JAGX Nasdaq
- SCNI Nasdaq
- Market Cap
- JAGX 3.1M
- SCNI 2.8M
- IPO Year
- JAGX N/A
- SCNI N/A
- Fundamental
- Price
- JAGX $4.67
- SCNI $2.85
- Analyst Decision
- JAGX
- SCNI
- Analyst Count
- JAGX 0
- SCNI 0
- Target Price
- JAGX N/A
- SCNI N/A
- AVG Volume (30 Days)
- JAGX 39.3K
- SCNI 10.1K
- Earning Date
- JAGX 03-31-2025
- SCNI 05-14-2025
- Dividend Yield
- JAGX N/A
- SCNI N/A
- EPS Growth
- JAGX N/A
- SCNI N/A
- EPS
- JAGX N/A
- SCNI 8.20
- Revenue
- JAGX $11,689,000.00
- SCNI $452,000.00
- Revenue This Year
- JAGX $18.18
- SCNI N/A
- Revenue Next Year
- JAGX $40.06
- SCNI N/A
- P/E Ratio
- JAGX N/A
- SCNI $0.34
- Revenue Growth
- JAGX 19.75
- SCNI N/A
- 52 Week Low
- JAGX $4.40
- SCNI $2.23
- 52 Week High
- JAGX $540.00
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- JAGX 20.41
- SCNI 34.84
- Support Level
- JAGX $4.41
- SCNI $2.64
- Resistance Level
- JAGX $4.97
- SCNI $2.86
- Average True Range (ATR)
- JAGX 0.88
- SCNI 0.25
- MACD
- JAGX 0.09
- SCNI -0.06
- Stochastic Oscillator
- JAGX 3.35
- SCNI 35.93
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.